At a glance
| Target family | Amylin-related receptors |
|---|---|
| Studied route | Subcutaneous injection |
| Development | Monotherapy and combination programs |
| Combination name | CagriSema with semaglutide |
| Common trial effects | Nausea and other GI symptoms |
Overview
Amylin is a pancreatic hormone involved in meal-related satiety. Cagrilintide extends that signaling approach through a long-acting engineered peptide. A phase 2 monotherapy study established dose-related weight reduction in adults without diabetes, and later combination trials studied cagrilintide alongside semaglutide. Those programs ask different questions: one tests amylin-based treatment by itself, the other combines amylin and GLP-1 activity. A favorable combination result cannot simply be assigned to cagrilintide alone. The current knowledge base therefore retains separate canonical records for cagrilintide and the two-drug combination.
How it works
Cagrilintide engages amylin-related receptor signaling, including receptor complexes formed from calcitonin receptors and receptor-activity-modifying proteins. These pathways influence satiation and food intake through brain circuits distinct from, but overlapping functionally with, GLP-1 signaling. Its prolonged activity supports investigation as a weekly injection. The intended mechanism is pharmacologic appetite regulation; it is not replacement for a diagnosed general amylin-deficiency syndrome.
What is being developed
Monotherapy trials examine weight management in eligible adults. Combination development adds semaglutide to target another appetite pathway. These are pharmacologically related strategies but do not have identical exposure, trial populations or tolerability.
Monotherapy evidence
The phase 2 trial enrolled 706 adults and followed treatment for twenty-six weeks. Cagrilintide produced greater mean weight reduction than placebo, with gastrointestinal and administration-site events commonly reported. The study supported further development rather than establishing long-term cardiovascular benefit.
Supporting sources [1]
What combination studies add
REDEFINE 1 included separate cagrilintide, semaglutide, combination and placebo groups. That design helps distinguish each component from the combination. The larger average combination effect should not be advertised as the expected result from cagrilintide alone.
Supporting sources [2]
What is known and still unknown
Nausea, constipation, diarrhea and injection-site reactions appeared in monotherapy research. Longer and larger studies are needed to clarify uncommon harms, durability and use in populations not represented in early trials. A positive short-term tolerability assessment is not proof of unrestricted safety.
Current status and product identity
Cagrilintide remains investigational in the sources reviewed. FDA has specifically cautioned about unapproved weight-loss products containing it. Trial registration and a commercial research listing do not establish marketing approval or confirm the contents of a purchased product.
Supporting sources [3]
Common questions
Is cagrilintide a GLP-1 medicine? It is an amylin-pathway agonist; semaglutide supplies the GLP-1 component in CagriSema.
Can CagriSema results be attributed entirely to cagrilintide? No. Combination studies assess the combined regimen and its comparators. Cagrilintide monotherapy has its own evidence, and its independent effect should be taken from the appropriate study arm rather than the combination's headline result.
Reading this profile
Jurisdiction: United States — investigational; no FDA-approved cagrilintide medicine identified as of 2026-10-27.. Molecular class: Long-acting amylin analog peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗Original research · Checked 2026-10-27
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. ↗Original research · Checked 2026-10-27
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss ↗Regulatory source · Checked 2026-10-27
- ClinicalTrials.gov: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide ↗Clinical trial source · Checked 2026-10-27